Navigation Links
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application

SARASOTA, Fla., July 11, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"), has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND") application before granting the Company permission to start its clinical trial in the US.

Dr. Chris Chapman, RCP's President, commented, "We appreciate the agency's review and comments on our IND. When we receive the agency's official comments and/or recommendations, we will respond expeditiously. We look forward to moving this important product through the regulatory process."

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014.  We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

About Rock Creek Pharmaceuticals, Inc.

Rock Creek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for inflammatory conditions, clinical immunology, neurological disease and behavioral health.  Additionally, through its subsidiary RCP Development, the Company is engaged in the manufacturing and sale of nutraceutical dietary supplements designed to promote maintenance of a healthy metabolism and lifestyle. 

For more information, visit:

Logo -

Ted Jenkins
Vice President, Corporate Strategy, Development, Investor Relations
Rock Creek Pharmaceuticals


SOURCE Rock Creek Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. AMG Medical Inc. Selects Saddle Creek for Multichannel Fulfillment
2. A Forever Recovery Battle Creek, MI: Increasing Recreational Drug Use in Colleges Creates Risk for Addictions
3. Creekridge Capital Continues Vendor Growth within Technology
4. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
5. Creekridge Capital Announces Record Volume
6. Creekridge Capital Adds Revolving Credit Specialist
7. Creekridge Capital Expands Healthcare Sales Team
8. Creekridge Capital Launches Vendor Sales Training Program
9. Creekridge Capital Grows Healthcare Sales Team
10. Creekridge Breaks Monthly and Quarterly Volume Records
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
(Date:12/1/2015)... A federal court has denied the state of ... filed by the Pharmaceutical Care Management Association (PCMA) challenging the ... law that forces employers and consumers to pay drugstores higher ... must now defend a law that raises health care ... Mark Merritt . --> Arkansas ...
(Date:12/1/2015)... 1, 2015 Pharma Tech Outlook recently conducted ... Clinical Data Management Solution Providers - 2015 .  After ... comprising CEOs, CIOs, VCs, analysts, and the Pharma Tech ... of top 10 clinical data management solution providers (check ... 14 and 36 respectively). --> ...
(Date:12/1/2015)... VERONA, Va. , Dec. 1, 2015 /PRNewswire/ ... today unveiled a new corporate logo and brand ... in the design and engineering of bladed products ... --> --> Serving ... fiber, glass, and auto glass equipment, AccuTEC,s product ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... The Multiple System Atrophy Coalition has announced the launch of its MSA Can’t ... today to coincide with Giving Tuesday 2015, a global day of fundraising. , ... be productive, to do simple daily activities like walking to the mailbox and eating ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Royal River ... a new study that found post-menopausal women who took the nutritional supplement creatine, along ... women who trained but did not take creatine. , The report is part of ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... 01, 2015 , ... December 1, 2015 -- InstantLabs is ... growing product line of food safety and seafood fraud prevention tools. , The ... allow InstantLabs to offer fast, reliable species identification for the four most popular ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):